Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

High Density Lipoprotein and it's Dysfunction.

Eren E, Yilmaz N, Aydin O.

Open Biochem J. 2012;6:78-93. doi: 10.2174/1874091X01206010078. Epub 2012 Jul 27.

3.

Anti-oxidant properties of high-density lipoprotein and atherosclerosis.

Podrez EA.

Clin Exp Pharmacol Physiol. 2010 Jul;37(7):719-25. doi: 10.1111/j.1440-1681.2010.05380.x. Epub 2010 Mar 30. Review.

4.

HDL-A molecule with a multi-faceted role in coronary artery disease.

Arora S, Patra SK, Saini R.

Clin Chim Acta. 2016 Jan 15;452:66-81. doi: 10.1016/j.cca.2015.10.021. Epub 2015 Oct 28. Review.

PMID:
26519003
5.

HDL-C: role as a risk modifier.

Barter P.

Atheroscler Suppl. 2011 Nov;12(3):267-70. doi: 10.1016/S1567-5688(11)70885-6. Review.

PMID:
22152280
6.

High-density lipoprotein cholesterol and residual cardiometabolic risk in metabolic syndrome.

Cannon CP.

Clin Cornerstone. 2007;8 Suppl 6:S14-23. Review.

PMID:
17948363
7.

Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.

Hersberger M, von Eckardstein A.

Drugs. 2003;63(18):1907-45. Review.

PMID:
12930163
8.

Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.

Hausenloy DJ, Yellon DM.

Heart. 2008 Jun;94(6):706-14. doi: 10.1136/hrt.2007.125401. Review.

PMID:
18480348
9.

Low-density lipoprotein apheresis: an evidence-based analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2007;7(5):1-101. Epub 2006 Nov 1.

10.

Lipids and cardiovascular disease: do the findings and therapy apply equally to men and women?

LaRosa JC.

Womens Health Issues. 1992 Summer;2(2):102-11; discussion 111-3.

PMID:
1617306
11.

Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.

Hausenloy DJ, Yellon DM.

Postgrad Med J. 2008 Nov;84(997):590-8. doi: 10.1136/hrt.2007.125401. Review.

PMID:
19103817
12.

High-density lipoprotein-mediated anti-atherosclerotic and endothelial-protective effects: a potential novel therapeutic target in cardiovascular disease.

Besler C, Heinrich K, Riwanto M, Lüscher TF, Landmesser U.

Curr Pharm Des. 2010 May;16(13):1480-93. Review.

PMID:
20196740
13.

High-Density Lipoprotein Processing and Premature Cardiovascular Disease.

Rosales C, Gillard BK, Gotto AM Jr, Pownall HJ.

Methodist Debakey Cardiovasc J. 2015 Jul-Sep;11(3):181-5. doi: 10.14797/mdcj-11-3-181.

14.

Modulation of high-density lipoprotein cholesterol metabolism and reverse cholesterol transport.

Hersberger M, von Eckardstein A.

Handb Exp Pharmacol. 2005;(170):537-61. Review.

PMID:
16596814
15.

High-density lipoprotein-based drug discovery for treatment of atherosclerosis.

Du Y, Wang L, Hong B.

Expert Opin Drug Discov. 2015;10(8):841-55. doi: 10.1517/17460441.2015.1051963. Epub 2015 May 28. Review.

PMID:
26022101
16.

High Density Lipoprotein Cholesterol Increasing Therapy: The Unmet Cardiovascular Need.

Cimmino G, Ciccarelli G, Morello A, Ciccarelli M, Golino P.

Transl Med UniSa. 2014 Sep 1;12:29-40. eCollection 2015 May-Aug.

17.

Targeting high-density lipoproteins: update on a promising therapy.

Verdier C, Martinez LO, Ferrières J, Elbaz M, Genoux A, Perret B.

Arch Cardiovasc Dis. 2013 Nov;106(11):601-11. doi: 10.1016/j.acvd.2013.06.052. Epub 2013 Sep 25.

18.

High-density lipoprotein: key molecule in cholesterol efflux and the prevention of atherosclerosis.

Meurs I, Van Eck M, Van Berkel TJ.

Curr Pharm Des. 2010 May;16(13):1445-67. Review.

PMID:
20199377
19.

Pitavastatin: novel effects on lipid parameters.

Chapman MJ.

Atheroscler Suppl. 2011 Nov;12(3):277-84. doi: 10.1016/S1567-5688(11)70887-X. Review.

PMID:
22152282
20.

Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.

Cziraky MJ, Watson KE, Talbert RL.

J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. Review.

PMID:
19891279
Items per page

Supplemental Content

Write to the Help Desk